The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
复制标题
减少剂量伊达比星治疗老年急性髓系白血病的疗效。
DOI：
10.1093/jjco/hyt111
复制
发表时间：
2013
期刊：
影响因子：
2.4
通讯作者：
and Kurokawa M.
中科院分区：
文献类型：
--
作者：
Kobayashi T;Ichikawa M;Nannya Y;and Kurokawa M.
采用2天12 mg/m2的伊达比星和5天的阿糖胞苷(100 mg/m2)(2+5)的减量化疗方案治疗65~74岁患者，并与55~74岁的患者(3+7)进行回顾性比较。1999年至2009年，我们治疗了20例65~74岁的患者(2+5)和23例55~74岁的患者(3+7)。首次诱导完全缓解率分别为50.0%和69.6%(P=0.203)。两年总生存率分别为55.9%和32.3%，两年无复发生存率分别为15.7%和36.5%。总生存率和无复发生存率差异无统计学意义(P分别为0.726和0.413)。老年组2+5治疗效果与3+7治疗效果相比差异无统计学意义。因此，不能耐受3+7的老年患者仍应受益于2+5。
We evaluated whether reduced-dose chemotherapy with 2 days of idarubicin (12 mg/m2) and 5 days of cytarabine (100 mg/m2) (2 + 5) is effective for patients aged 65–74 by retrospectively comparing the results with those aged 55–64 treated with 3 + 7. In 1999–2009, we treated 20 patients aged 65–74 with 2 + 5, and 23 patients aged 55–64 with 3 + 7. The complete remission rates by the first induction were 50.0 and 69.6% for older and younger groups (P= 0.203). Two-year overall survival rates were 55.9 and 32.3% for older and younger groups; 2-year rates of relapse-free survival for all these patients were 15.7 and 36.5%. The differences in overall and relapse-free survival were statistically insignificant (P= 0.726 and 0.413, respectively). The treatment results of 2 + 5 for the older group were not significantly worse compared with those of 3 + 7 for the younger. Therefore, elderly patients who do not tolerate 3 + 7 should still benefit from 2 + 5.